XML 42 R7.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Millions
6 Months Ended 12 Months Ended
Jun. 30, 2019
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Statement of Cash Flows [Abstract]          
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest   $ (118.0) $ (352.0) $ (242.0)  
Adjustments to reconcile net loss to cash provided by operating activities:          
Depreciation, amortization and impairments   647.0 690.0 683.0  
Change in deferred income taxes   (21.0) (33.0) (6.0)  
Stock-based compensation   37.0 44.0 27.0  
Noncash Interest Expense   25.0 25.0 21.0  
Earnings from equity investments, net   (24.0) (25.0) (27.0)  
Distributed earnings from equity investments   26.0 33.0 33.0  
Loss (gain) on sale of assets and other, net   6.0 (16.0) 1.0  
Loss on debt financing transactions   100.0 93.0 38.0  
Gain on remeasurement of debt   (9.0) (43.0) 0.0  
Contingent acquisition consideration fair value adjustment   2.0 29.0 0.0  
Changes in assets and liabilities, net of effects of acquisitions:          
Accounts and notes receivable, net   (55.0) 32.0 (48.0)  
Inventories   (20.0) 22.0 (2.0)  
Other assets and liabilities   (31.0) (27.0) (36.0)  
Accounts payable and accrued liabilities   (19.0) (126.0) 65.0  
Net cash provided by operating activities   546.0 346.0 507.0  
Cash flows from investing activities:          
Payments to Acquire Other Productive Assets   285.0 391.0    
Capital expenditures   (285.0) (391.0) (294.0)  
Acquisitions of businesses and assets, net of cash acquired   0.0 (297.0) (58.0)  
Acquisitions and additions to equity method investments   (1.0) (180.0) (107.0)  
Distributions of capital from equity investments   23.0 30.0 34.0  
Proceeds from asset sales and other   0.0 40.0 10.0  
Net cash used in investing activities   (263.0) (798.0) (415.0)  
Cash flows from financing activities:          
Borrowings under revolving credit facility   270.0 560.0 475.0  
Repayments under revolving credit facility   (400.0) (585.0) (170.0)  
Proceeds from issuance of senior notes and term loans   2,300.0 2,512.0 2,112.0  
Repayment of assumed NYX and other acquisitions debt   0.0 (290.0) 0.0  
Payments on long-term debt   (44.0) (39.0) (23.0)  
Repayments of senior notes and term loans (including redemption premium)   (2,523.0) (2,210.0) (1,693.0)  
Payments of debt issuance and deferred financing costs   (35.0) (38.0) (59.0)  
Payments on license obligations   (40.0) (45.0) (53.0)  
Proceeds From Sale Of Finance Receivables, Financing Activities   11.0 0.0 0.0  
Net proceeds from the sale of SciPlay common stock   342.0 0.0 0.0  
Payments of deferred SciPlay common stock offering costs   (9.0) 0.0 0.0  
Net redemptions of common stock under stock-based compensation plans and other   (1.0) (21.0) (9.0)  
Net cash (used in) provided by financing activities   (129.0) (156.0) 580.0  
Effect of exchange rate changes on cash, cash equivalents and restricted cash   1.0 (6.0) 5.0  
Increase (decrease) in cash, cash equivalents and restricted cash   155.0 (614.0) 677.0  
Cash, cash equivalents and restricted cash, beginning of period $ 220.0 220.0 834.0 157.0  
Cash, cash equivalents and restricted cash, end of period   375.0 220.0 834.0 $ 157.0
Supplemental cash flow information:          
Cash paid for interest 549.0     633.0 575.0
Income taxes paid 41.0     33.0 38.0
Payment for Contingent Consideration Liability, Operating Activities   $ 26.0 0.0 0.0  
Non-cash investing and financing transactions:          
Note Rollover     0.0 3,275.0 6,030.0
Non-cash additions to intangible assets related to license agreements     $ 0.0 138.0 26.0
NYX non-cash consideration transferred (including 2017 acquisition of ordinary shares) $ 0.0     $ 93.0 $ 0.0